What is Arctic Bioscience?
Arctic Bioscience is a Norway-based biotechnology firm dedicated to the development and commercialization of pharmaceutical and nutraceutical products. Its core focus lies in harnessing bioactive compounds derived from marine sources, particularly herring roe, to create innovative health solutions. The company integrates advanced marine science with rigorous clinical research to produce both investigational treatments for inflammatory conditions and premium omega-based ingredients for the global market. Arctic Bioscience manages the entire value chain, from research and development to production and market distribution, with a strong emphasis on sustainable practices and scientific validation.
How much funding has Arctic Bioscience raised?
Arctic Bioscience has raised a total of $1.5M across 1 funding round:
Debt
$1.5M
Debt (2026): $1.5M, investors not publicly disclosed
What's next for Arctic Bioscience?
The recent major strategic investment signals a pivotal moment for Arctic Bioscience, likely enabling the company to accelerate its research pipeline, scale production capabilities, and expand its market reach. This enterprise-level backing suggests a transition towards broader commercialization and potentially further clinical trials for its therapeutic candidates. The company is well-positioned to leverage its unique marine-derived compounds for significant growth in both the pharmaceutical and nutraceutical industries, aiming to solidify its position as a leader in marine biotechnology.
See full Arctic Bioscience company page
